Vanguard Asset Management
CAI

Vanguard Asset Management’s Caris Life Sciences CAI Stock Holding History

Vanguard Asset Management’s Portfolio CAI Stock Details CAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$402K Hold
22,584
– – ﹤0.01% 2267
2026
Q1 		$404K Buy
+22,584
New +$494K ﹤0.01% 2189

Other funds holding CAI

JHWEPV
J. H. Whitney Equity Partners VI New Canaan, Connecticut $201M AUM
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
SSP
Sixth Street Partners Dallas, Texas $579M AUM 2.46% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Los Angeles Capital Management
Los Angeles Capital Management Los Angeles, California $27.2B AUM 43.16% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

Vanguard Asset Management's CAI Position: Q2 2026 in Review

Vanguard Asset Management held its Caris Life Sciences (CAI) position steady in Q2 2026 at 22,584 shares worth $402K. The position accounts for ﹤0.01% of the portfolio, ranked #2267.

Vanguard Asset Management first reported a position in CAI in Q1 2026 and has held it in 2 quarters since. The position peaked at $404K in Q1 2026. 228 funds tracked by Wall St. Rank hold CAI as of Q2 2026.

  • Vanguard Asset Management held 22,584 shares of Caris Life Sciences worth $402K as of Q2 2026.
  • Vanguard Asset Management left its Caris Life Sciences share count unchanged in Q2 2026.
  • Caris Life Sciences made up ﹤0.01% of Vanguard Asset Management's portfolio in Q2 2026, its #2267 holding.
  • Vanguard Asset Management first reported a position in Caris Life Sciences in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Asset Management's Caris Life Sciences position peaked at $404K in Q1 2026.
  • 228 funds tracked by Wall St. Rank held Caris Life Sciences as of Q2 2026.

Based on Vanguard Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.